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Purpose: Transplantation of human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells
offers the potential for benefit in macular degeneration. Previous trials have reported improved visual acuity (VA),
but lacked detailed analysis of retinal structure and function in the treated area.
Design: Phase 1/2 open-label dose-escalation trial to evaluate safety and potential efficacy (clinicaltrials.gov
identifier, NCT01469832).
Participants: Twelve participants with advanced Stargardt disease (STGD1), the most common cause of
macular degeneration in children and young adults.
Methods: Subretinal transplantation of up to 200 000 hESC-derived RPE cells with systemic immunosup-
pressive therapy for 13 weeks.
Main Outcome Measures: The primary end points were the safety and tolerability of hESC-derived RPE cell
administration. We also investigated evidence of the survival of transplanted cells and measured retinal structure
and function using microperimetry and spectral-domain OCT.
Results: Focal areas of subretinal hyperpigmentation developed in all participants in a dose-dependent
manner in the recipient retina and persisted after withdrawal of systemic immunosuppression. We found no
evidence of uncontrolled proliferation or inflammatory responses. Borderline improvements in best-corrected VA
in 4 participants either were unsustained or were matched by a similar improvement in the untreated contralateral
eye. Microperimetry demonstrated no evidence of benefit at 12 months in the 12 participants. In one instance at
the highest dose, localized retinal thinning and reduced sensitivity in the area of hyperpigmentation suggested the
potential for harm. Participant-reported quality of life using the 25-item National Eye Institute Visual Function
Questionnaire indicated no significant change.
Conclusions: Subretinal hyperpigmentation is consistent with the survival of viable transplanted hESC-
derived RPE cells, but may reflect released pigment in their absence. The findings demonstrate the value of
detailed analysis of spatial correlation of retinal structure and function in determining with appropriate sensitivity
the impact of cell transplantation and suggest that intervention in early stage of disease should be approached
with caution. Given the slow rate of progressive degeneration at this advanced stage of disease, any protection
against further deterioration may be evident only after a more extended period of
observation. Ophthalmology 2018;-:1e11 Crown Copyright ª 2018 Published by Elsevier Inc. on behalf of the
American Academy of Ophthalmology. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Supplemental material available at www.aaojournal.org.Embryonic stem cells are a potentially valuable source of
donor cells for therapeutic repair and regeneration. Their
pluripotency and innate capacity for self-renewal offer a
virtually unlimited supply of highly specialized cells for
therapeutic transplantation, but also present a potential risk
of harm from uncontrolled proliferation and unintended
differentiation. Their impact in experimental models hasCrown Copyright ª 2018 Published by Elsevier Inc. on behalf of the American
Academy of Ophthalmology. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).been investigated extensively, but evidence of their safety
and potential efficacy in humans is limited. Embryonic stem
cells have attracted attention for their potential value in a
broad range of degenerative conditions, including those
affecting the brain and eye. The eye has unique advantages
as a target organ for cell transplantation. The retina is an
extension of the brain that is readily accessible to surgical1https://doi.org/10.1016/j.ophtha.2018.04.037
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lends itself to the targeted delivery of cellular therapies.
The highly compartmentalized structure of the globe restricts
potential dissemination locally and systemically. The intra-
ocular environment is relatively protected against systemic
immune responses that threaten allograft survival. Retinal
microstructure can be observed in detail in the living eye
noninvasively owing to the optical transparency of ocular
media, and retinal function can be mapped topographically
with exquisite sensitivity. The impact of intervention within a
defined target region of the retina can be determined with
confidence by comparison with untreated regions within the
same eye and in the contralateral eye, which offer invaluable
intraocular and intraindividual controls for the natural history
of the condition and variability in performance.
Stargardt disease (STGD1) is the most common cause of
macular degeneration in children and young adults. The con-
dition originates in disease-causing sequence variants in the
ABCA4 gene1 and results in progressively severe impairment
of sight. The ABCA4 gene encodes a rim protein located on
the intracellular disc membranes of light-sensitive photore-
ceptor cells that play an essential role in the retinoid cycle.2
Gene defects result in accelerated accumulation of a putative
toxic metabolite, Di-retinoid-pyridinium-ethanolamine,
within the underlying phagocytic retinal pigment epithelial
(RPE) cells, leading to cell dysfunction and eventual cell
death3 with progressive atrophy expanding from the central
macula.4 Retinal pigment epithelial cells support the
function and survival of overlying photoreceptor cells by
multiple mechanisms, including recycling of visual pigment
and phagocytosis of outer segments.5 Degeneration of RPE
cells leads to secondary dysfunction and degeneration of
overlying photoreceptor cells, and consequently
progressively severe impairment of sight. Stargardt disease
currently is untreatable, but replenishment of degenerating
RPE cells with healthy cells offers the possibility of benefit
by better supporting the function and survival of overlying
photoreceptor cells, and consequently improving or
protecting sight for a period limited by the consequences of
the underlying photoreceptor disorder. A similar approach
may benefit atrophic age-related macular degeneration,
which shares key features with STGD1, including progressive
atrophy of RPE and overlying photoreceptor cells. However,
differences in their cause and progression are likely to influ-
ence the potential benefit of subretinal administration of hu-
man embryonic stem cell (hESC)-derived RPE cell
suspensions. For example, age-related changes in Bruch’s
(basement) membrane and chronic inflammation in age-
related macular degeneration may influence the adhesion and
survival of donor cells.
In experimental models of retinal degeneration, subretinal
injection of hESC-derived RPE cell suspensions can protect
photoreceptor cells and retinal function.6,7 In human partici-
pants with STGD1, subretinal injection of up to 150 000
hESC-derived RPE cells resulted in no serious adverse events
related to the transplanted cells.8e10 However, assessment of
visual function has been limited. Herein we present the results
of a dose-escalation trial of up to 200 000 hESC-derived RPE
cells in 12 participants. To mitigate the risk of harm, we
chose to investigate the safety of hESC-derived RPE2transplantation in the poorer-seeing eye of individuals with
advanced disease, acknowledging that any potential for
benefit would be limited in this context by established
degeneration of photoreceptor cells. Retinal degeneration in
STGD1 typically advances progressively by expansion from
the macula. We chose to administer cells to a target area,
predefined for each study eye, extending from relatively well-
preserved functional retina across a transitional zone of pro-
gressive degeneration to an area of atrophic nonfunctional
retina. This afforded us the opportunity both to determine the
safety of the transplanted cells in relatively healthy retina and
to explore the potential benefit to function and survival of
overlying photoreceptor cells in the degenerating and atrophic
areas. By defining the target zone in the retina of each study
eye before intervention, according to the distribution of dis-
ease severity and preferred locus of fixation, we were able to
evaluate in detail the structure and function of this region
before intervention using OCT, autofluorescence imaging,
full-field perimetry, and microperimetry. For assessment of
visual function, we established each participants’ testeretest
variability for each test by means of multiple testing at
baseline and controlled for the natural history of the condi-
tion, learning effects, and performance variability by com-
parison with the contralateral uninjected eye, on the basis that
disease progression in an individual is symmetrical11 and that
monocular performance of the contralateral uninjected eye is
not influenced by the intervention. We considered that for
each participant, changes in performance of both eyes
symmetrically would indicate disease progression, learning
effects, or both and that differences between the eyes may
indicate a consequence of the intervention.Methods
Trial Design
We performed a phase 1/2 open-label multicenter dose-escalation
trial in 12 adult participants to evaluate the safety and tolerability
of subretinal transplantation of hESC-derived RPE cells. The
intervention was unmasked. The study received the approval of the
Medicines and Health Products Regulatory Authority, the United
Kingdom Gene Therapy Advisory Committee, and the Moorfields
Eye Hospital Research Governance Committee. We provided
potential candidates with detailed information, including an
explanation of the aims of the trial and the possible consequences
of participation. Participants provided their written informed con-
sent before enrolment. We performed the study in accordance with
the tenets of the Declaration of Helsinki and registered the trial at
clinicaltrials.gov (identifier, NCT01469832).
Trial Participants
We enrolled 12 participants with clinical features of STGD1,
electroretinographic evidence of generalized rod and cone photo-
receptor cell dysfunction, and molecular characterization of
mutations in ABCA4. We excluded candidates in whom the visual
acuity (VA) of their poorer-seeing eye was 20/400 or better, those
with any history of malignant neoplasia or significant ocular
pathologic features other than STGD1, any contraindication to
systemic immunosuppression or surgery under general anaesthesia,
and women who were pregnant or lactating. We enrolled partici-
pants sequentially into escalating dose groups of 50 000, 100 000,
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included 3 participants. For each participant, we selected the
poorer-seeing eye (according to dominance and VA) as the study
eye for intervention; the better-seeing contralateral eye served as an
untreated control for intraindividual natural history and perfor-
mance variability.
Intervention
Retinal pigment epithelial cells were generated from the hESC line
MA09 in accordance with good manufacturing practice. The hESC
bank was thawed and expanded on mitomycin Cetreated mouse
embryonic fibroblasts for 3 passages. Human embryonic stem cells
were dissociated and seeded to allow embryoid body formation.
Pigmented RPE patches then were isolated with collagenase from
cellular outgrowths. After purification and trypsinization, the RPE
cells were expanded and cryopreserved at passage 2 for clinical
application.We characterized RPE cells in process and after freezing
and formulation, including karyotyping, pathogen and phagocytosis
assay testing, and differentiation and purity evaluation by morpho-
logic assessment, quantitative polymerase chain reaction, and
quantitative immunohistochemistry for RPE and hESC markers. On
the day of transplantation, cells were thawed from cryopreserved
hESC-derived RPE cell banks, formulated at the appropriate con-
centration, stained to exclude bacterial contamination, and delivered
to the operating room for administration.8
The surgical procedure was conducted under general anaes-
thesia. We performed 3-port pars plana vitrectomy, with separation
of the posterior hyaloid from the posterior pole toward the equator.
Administration of hESC-derived RPE cells was preceded by
subretinal injection of up to 0.2 ml Hartmann’s solution using a
41-gauge cannula to establish the target tissue plane and to mini-
mize unintended administration of cells into the vitreous or
choroid. The hESC-derived RPE cell suspension, reconstituted to
the appropriate concentration in 150 ml, was injected using a
38-gauge subretinal cannula (MedOne PolyTip Cannula 23/38;
MedOne Surgical, Sarasota, FL) into the preformed bleb of
Hartmann’s solution. After subretinal injection, we performed a
washout of the vitreous cavity by continuous infusion and aspira-
tion of fluid to minimize the presence of donor cells remaining in
this compartment. Participants were advised to maintain a supine
position for 6 hours after surgery.
Human embryonic stem cell-derived RPE cells were delivered
into a preselected transition region of the retina, defined for each
participant as a region extending from an area of relatively pre-
served structural integrity and function to an area of atrophic
nonfunctional retina. The rationale was to investigate the safety of
hESC-derived RPE cell administration in areas of relatively well-
preserved retina and the potential benefit in areas of retinal
dysfunction and atrophy. The target region was defined before
surgery for the study eye of each participant with regard to the
distribution of the disease severity and preferred locus of fixation
using spectral-domain (SD) OCT, fundus autofluorescence (FAF)
imaging, and microperimetry. We defined target regions close to
the preferred locus of fixation to optimize the quality of structural
and functional assessment.
Tomanage the risk of immune rejection of the transplanted hESC-
derived RPE cells, participants were prescribed oral immunosup-
pression in the perioperative period. Low-dose tacrolimus (0.1mg/kg)
was divided into 2 daily doses from 1 week before transplantation,
titrated to achieve trough serum levels of 3 to 7 ng/ml, andmaintained
until week 6 after transplantation, when it was discontinued. Myco-
phenolate was commenced on the day of surgery (day 0) in an esca-
lating dose regimen: 0.25 g twice daily (day 0 to day 1); 0.5 g twice
daily (day 2 to day 3), and 1 g twice daily from day 4 until 12 weeks
after transplantation, when it was discontinued. Participants also wereprescribed a standard postvitrectomy regimen of topical antibiotics
(chloramphenicol 0.5% 4 times daily for 7 days) and topical nonste-
roidal anti-inflammatory drugs (ketorolac 0.5% 4 times daily for 4
weeks).
Outcome Measures
The primary end points were the safety and tolerability of hESC-
derived RPE cells as defined by the absence of any grade 2 or
more (National Cancer Institute grading system) adverse event
relating to the transplanted cells, any evidence that the cells were
contaminated with an infectious agent, any evidence that the cells
showed potential of tumorigenicity, or a combination thereof.
Secondary end points included safety of the surgical procedure,
dose selection for future studies, evidence of donor cell survival
and engraftment in the target location, and retinal function as
measured by electroretinography. Exploratory end points included
VA, color discrimination, retinal sensitivity by perimetry, and
quality of life (assessed with the 25-item National Eye Institute
Visual Function Questionnaire).
We evaluated participants at baseline and after hESC-derived RPE
cell transplantation at intervals for 12 months. We performed exami-
nation by slit-lamp biomicroscopy and indirect binocular ophthal-
moscopy, color fundus photography, FAF imaging, fundus fluorescein
angiography, and SDOCT.Wemeasured best-corrected VA (BCVA)
and color discrimination (Universal Colour Discrimination Test) and
performed microperimetry (Nidek MP-1, NIDEK Inc, Fremont, CA)
full-field static perimetry (Octopus 900, Haag-Streit, Switzerland),
Goldmann kinetic perimetry, and electroretinography (including full-
field, pattern, and multifocal electroretinography to international
standards using gold-foil electrodes). We used standardized protocols
and a fixed sequence of test patterns. We assessed participants’ sys-
temic health by physical examination results, electrocardiography
results, cancer screening results, and hematologic and serologic re-
sults. After completion of the initial 12-month evaluation period,
participants were followed up for long-term safety assessments, the
anticipated duration of which is lifelong.
Statistical Analysis
The small sample size was not designed for statistical analysis. The
end points for efficacy were solely descriptive and were defined as
any improvement in visual function beyond the testeretest vari-
ability within the full cohort for each assessment, determined by
means of 1-way analysis of variance with the use of multiple
measurements at baseline.12
Role of the Funding Source
The funder of the study participated in the study design, data
analysis and interpretation, and writing of the report. The corre-
sponding author had full access to all the data in the study and had
final responsibility for the decision to submit for publication.
Results
Administration of Human Embryonic Stem Cell-
Derived Retinal Pigment Epithelial Cell
Suspension
We administered hESC-derived RPE cells to 12 participants (age
range, 34e53 years) with molecularly proven advanced STGD1
(Table 1). The hESC-derived RPE cells were reconstituted and
administered subretinally by 2 of the authorsdpatients 1 through
11 by J.W.B.B. and patient 12 by D.S.dto the predefined target
regions, which were inferior to the inferotemporal vascular arcade3
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(patients 5 and 11; Fig 1). We performed intraoperative
prophylactic retinopexy for pre-existing pigmented retinal breaks
in 2 participants (patients 3 and 5) and for atrophic retinal holes in
2 participants (patients 10 and 11). In 1 participant (patient 12),
cryoretinopexy and injection of sulphahexafluouride gas were
performed for 2 small superonasal retinal tears and a small infe-
rotemporal retinal dialysis with localized avulsion of pars plana
epithelium. In all eyes, the bleb of subretinal fluid resorbed clini-
cally within 24 hours, with no persistent or unplanned retinal
detachment. Small subretinal hemorrhages at the injection sites
were evident in 2 participants (patients 1 and 12). Mild post-
operative vitreous cavity hemorrhage in 1 participant (patient 5),
arising from a pars plana entry site, cleared spontaneously within 4
weeks. A mild asymptomatic posterior subcapsular lens opacity
was evident in 1 participant (patient 6) at month 9. Adverse events
related to immunosuppression in 5 participants (patients 5, 6, 7, 10,
and 12) included lethargy, headache, nausea, and herpes simplex
virus 1 (HSV1) reactivation. All participants completed 12 weeks
of immunosuppression after transplantation.
We identified no evidence of acute immune rejection such as
vitreitis, retinitis, retinal exudates, retinal edema, or vascular
hyperpermeability. In no instance was intraretinal fluid evident on
OCT, and no change of clinical concern was apparent on fundus
fluorescein angiography. We found no evidence of adverse pro-
liferation of transplanted hESC-derived RPE cells either intraocu-
larly or on systemic screening by clinical examination (including
testicular and prostate examination in men and breast and pelvic
examination in women) or investigation (including fecal occult
blood test, chest radiography, thyroid function analysis, prostate-
specific antigen analysis, and cervical smear analysis, as
appropriate).Effect of Human Embryonic Stem Cell-Derived
Retinal Pigment Epithelial Cell Transplantation
on Retinal Structure
Within 4 weeks of administration of hESC-derived RPE cells, sub-
retinal hyperpigmentation developed within the area of injection of
the cell suspension in all 12 participants (Fig 1). The mean area of
subretinal hyperpigmentation increased progressively, at a rate that
seemed to be dose dependent during the first 3 months, and
subsequently slowed (Fig S1, available at www.aaojournal.org).
A subsequent modest reduction in area of subretinal
hyperpigmentation was evident in 2 participants (patients 4 and 9).
The mean area of subretinal pigmentation at 12 months was
correlated directly with the dose of hESC-derived RPE cells
administered (R2¼ 0.981; Fig S2, available at www.aaojournal.org).
Areas of subretinal hyperpigmentation corresponded on SDOCT
to a hyperreflective signal located between the photoreceptor cell
layer and the underlying Bruch’s membrane that persisted for 12
months in all eyes. Focal changes in FAF, which may be an indirect
indication of RPE cell function, were evident within the region of
cell administration. A relative predilection for the development of
hyperpigmentation at sites of retinal atrophy within the injected area
was evident. In 1 patient (patient 4), a circular region of atrophic
retina, which on SD OCT appeared to be devoid of RPE, developed
progressively confluent hyperpigmentation with increasing sub-
retinal hyperreflectivity on SD OCT and masking of choroidal
hyperreflectivity (Fig 2A). However, recovery of FAF in this area
was undetectable at 12 months (Fig 2Axii). Hyperpigmentation in
areas overlying surviving host RPE typically was associated with
reduced FAF, consistent with masking of the autofluorescence of
underlying host RPE (Fig 2B). We investigated the relationship
between hyperpigmentation and retinal thickness using SD OCT4in the 3 participants (patients 8, 9, and 10) whose fixation stability
enabled reliable serial analysis; in 2 participants (patients 8 and 9),
we identified no clear relationship; in 1 participant (patient 10),
who was administered the highest dose, retinal thinning was
evident in the hyperpigmented areas at 12 months (Fig S3,
available at www.aaojournal.org).
Focal preretinal pigmentation (on the inner surface of the retina)
developed in 2 participants (Fig 1). In 1 participant (patient 1),
preretinal pigmentation was associated with limited adherence to
advice to maintain a supine position after surgery; in this instance,
the area of preretinal pigmentation increased progressively during
the 12-month period, but subsequently stabilized (data not shown).
One participant (patient 12) demonstrated a nonpigmented and
noncontractile epiretinal membrane over the injection site at month
6; this subsequently stabilized in extent with nomeasurable effect on
visual function. Focal pigmented deposits were evident in the vit-
reous cavity in 2 participants (patients 6 and 7), both of whom
reported visual floaters.Effect of Human Embryonic Stem Cell-Derived
Retinal Pigment Epithelial Cell Transplantation
on Retinal Function
We measured no clinically significant decline or improvement in
retinal function by electroretinography in any of the participants
during the 12-month period. Participant-reported quality of life using
the 25-item National Eye Institute Visual Function Questionnaire
indicated no significant change. A transient reduction in BCVA of
operated eyes was evident in 7 participants (patients 2, 3, 4, 5, 8, 11,
and 12) after surgery and resolved within 96 days (range, 3e21
days; Fig S4, available at www.aaojournal.org). Borderline
improvements in BCVA were evident in 4 participants, although
these were either unsustained (patients 1, 7, and 10) or matched by
a similar improvement in the contralateral eye (patient 12). The
mean BCVA of the 150 000-cell dose improved to the limit of
baseline variability; for the other dose groups, the mean BCVA
remained within the limits of testeretest variability during the 12-
month period. The participants’ preferred loci of fixation were
unaltered (data not shown).
We investigated retinal sensitivity in detail using mesopic
microperimetry (NidekMP-1).Wemeasured retinal sensitivity at loci
in the macular area (central 20) in both the study eye (including a
variable portion of the transplanted area) and contralateral eye (in all
except patient 12) and calculated the change in sensitivity from
baseline (Fig S5, available at www.aaojournal.org). A borderline
improvement in retinal sensitivity of the study eye in 1 participant
(patient 7) was evident at 3 months only. The mean retinal
sensitivity in all 4 dose groups remained within the limits of the
testeretest variability.
For the study eyes of 8 participants (all except patients 1, 6, 7, and
12, for whom the assessment was unavailable or unreliable) we
measured in greater detail, using a stimulus grid of high density, the
sensitivity of the area of retina specifically targeted with the hESC-
derived RPE cell suspension. The total retinal sensitivities of each
eye and themean sensitivities of each dose group remainedwithin the
limits of testeretest variability during the 12-month period (Fig S6,
available at www.aaojournal.org). To quantify the spatial
correlation of retinal sensitivity with hyperpigmentation, we
measured the change in retinal sensitivity at 12 months at
hyperpigmented and nonhyperpigmented loci (Fig 3). The retinal
sensitivity at most loci remained within the limits of variability,
whether within or outside the transplanted area, and regardless of
the presence of hyperpigmentation (Fig 4); in 2 participants
administered higher doses (patients 8 and 10), retinal sensitivity at
hyperpigmented loci tended to be reduced. To demonstrate highly
Table 1. Participants and Dosing
Participant
number Age (yr) hESC-RPE dose Sex Study eye
Baseline Visual Acuity ETDRS LogMAR Genotype Pathogenic
variants on ABCA4 geneStudy eye Control eye
P1 34 50 000 M OD 1.29 1.23 c.768G>T (p.?)
c.5461-10T>C (p.?)
P2 44 M OS 1.36 1.39 c.4918C>T (p.Arg1640Trp)
c.6079C>T (p.Leu202Phe)
P3 46 M OS 1.33 1.33 c.2588G>C (p.Gly863Ala)
c.5461-10T (p.?)
c.2828G>A (p.Arg943Gln)
c.5603A>T (p.Asn1868Ile)
P4 41 100 000 M OS 1.39 1.35 c.4139C>T (p.Pro1380Leu)
c.5461-10C>T (p.?)
P5 51 M OD 1.37 1.39 c.454C>T (p.Arg152*)
c.1715G>A (p.Arg572Gln)
c.2588G>C (p.Gly863Ala)
c.6148G>C (p.Val2050Leu)
P6 44 F OD 1.84 1.84 c.161G>A (p.Cys54Try)
c.4462T>C (p.Cys1488Arg)
P7 40 150 000 M OD 1.84 1.36 c.666_678del (p.Lys223fs)
c.5461-10T>C (p?)
P8 53 M OS 1.27 1.23 c.2588G>C (p.Gly863Ala)
c.2828G>A (p.Arg943Gln)
c.5603A>T (p.Asn1868Ile)
P9 40 M OS 1.39 1.33 c.634C>T (p.Arg212Cys)
c.4319T>C (p.Phe1440Ser)
P10 50 200 000 M OS 1.25 1.19 c.1906C>T (p.Gln636*)
c.2588G>C (p.Gly863Ala)
P11 45 M OS 1.39 1.39 c.5461-10T>C
c.5929G>A (p.Gly1977Ser)
P12 45 M OS 1.09 1.10 c.2588G>C (p.Gly863Ala)
c.4469G>A (p.Cys1490Tyr)
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topographic contour maps using Visual Field Modelling and
Analysis software13 (Fig 3). Localized areas of improved retinal
sensitivity (for example, in patients 2, 3, 8, 9, and 11) were not
hyperpigmented, whereas retinal sensitivity in areas of
hyperpigmentation appeared unchanged or reduced (for example,
in patients 8 and 10).
We calculated the mean full-field retinal sensitivity in both the
study eyes and control eyes of each dose cohort (in all participants
except patients 6 and 12) by full-field static perimetry (Octopus
900). Deterioration in full-field sensitivity was evident in both the
study and control eyes of 2 participants (patients 2 and 4), and an
associated reduction in both the study and control eyes of the
100 000-cell dose cohort to the lower limit of testeretest variability
(Fig S7, available at www.aaojournal.org). The individual and
mean sensitivities otherwise were maintained within the limits of
variability for the 12-month period.
Because participants in the early stages of the trial described
subjective improvements after intervention in their sensitivity of
their study eye to color, we measured color vision in a subset of 4
participants (patients 8e11) using the Universal Colour Discrimi-
nation Test. A single assessment at baseline demonstrated poor
color discrimination in both eyes. Serial assessments after inter-
vention indicated no improvement in color vision that was specific
to the study eye (Fig S7).Discussion
Stargardt disease causes progressive and irreversible mac-
ular degeneration and severe impairment of sight.14 Repairof the compromised or degenerate RPE by transplantation
of healthy RPE cells offers the possibility of protecting or
improving sight by supporting the function or survival of
overlying photoreceptor cells. The results of the trial
satisfied its primary end point for safety, with no evidence
of inflammatory responses or uncontrolled intraocular or
systemic proliferation, after subretinal administration of up
to 200 000 hESC-derived RPE cells. There were no
serious adverse events related to the surgical procedure;
intraoperative adverse events resulted in no harm to visual
function beyond the immediate postoperative period. A brief
decline in BCVA in the operated eye after administration of
hESC-derived RPE cells was a predictable temporary
consequence of intraocular surgery. The development of
pigmented epiretinal membranes after injection of hESC-
derived RPE cells has been reported previously9 and is
consistent with reflux of cell suspension from the
subretinal space. Although we measured no associated
adverse impact on visual function at 12 months, the
longer-term significance has yet to be determined. Adverse
events related to the immunosuppressive medications
occurred during the period of their administration, but had
no impact subsequently.
The development of subretinal hyperpigmentation within
the injected area in all 12 participants was dose dependent and
associated in many instances with a hyperreflective signal on
OCT, suggesting survival of injected donor hESC-derived
RPE cells. The high density of pigmentation in these areas
may reflect a greater melanin content, higher density,5
Figure 1. Fundus photographs of recipient eyes at 12 months after transplantation. In each image, the retinotomy site is indicated by the green dot, and the
area of subretinal administration is outlined by the dotted black line. P ¼ patient.
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derived RPE cells. The presence of pigmented subretinal
material is not definitive evidence of donor cell survival and
alternatively may reflect persistence of melanin pigment after
their death,16,17 a consequence of transplantation that equally
could be dose dependent. We found no definitive evidence of
local accumulation of lipofuscin on FAF imaging to
demonstrate physiologic activity, and hence viability, of the
cells, although FAF may take longer than 12 months to
develop. Preferential engraftment of RPE cell transplants to6areas devoid of host RPE is plausible given the anchorage-
dependent properties of RPE cells18,19 and similarly has
been described in experimental in vivo studies.20 The
progressive local extension of hyperpigmentation during the
first 3 months and the predilection for areas of atrophy in
the recipient retina are consistent with local migration of
surviving donor cells, but may reflect subretinal migration
of released pigment.
To mitigate the risk of immune rejection of injected allo-
genic hESC-derived RPE cells, we administered systemic
Figure 2. Fundus photographs, OCT images, and fundus autofluorescence images in (A) patient 4 and (B) patient 10. A, In patient 4, fundus images
demonstrating the time-course of hyperpigmentation (Ai, Aiv, and Avii) are presented with corresponding OCT line scans, at lower and higher magni-
fication. A progressive increase in optical signal evident in the outer retina consistent with the continued presence of transplanted cells. B, In patient 10,
images demonstrating the time-course of hyperpigmentation (Bi, Bii, and Biii) are presented with the associated fundus autofluorescence images demon-
strating reduced signal consistent with masking of endogenous autofluorescence.
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Figure 3. Microperimetry images showing topography of retinal sensitivity. The retinal sensitivities at test loci in each study eye, measured by micro-
perimetry (Nidek MP-1) at baseline and 12 months, are superimposed on the respective fundus image. Each is presented with a corresponding topographic
contour map to illustrate the hill of vision of retinal sensitivity, constructed by interpolation of sensitivities at the test loci using Visual Field Modelling and
Analysis (VFMA) software. The blue line outlines the area of recipient retina administered human embryonic stem cell-derived retinal pigment epithelial
cell suspension. P ¼ patient; K ¼ thousand.
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Figure 4. Boxplots showing the change in retinal sensitivity from the baseline (mean of 3 baseline tests) as measured by microperimetry (Nidek MP-1) for
each test locus at month 12. Loci were stratified into 3 groups: outside the transplantation area (solid green dots), within the transplantation and associated
with subretinal hyperpigmentation (solid blue dots), or within the transplantation area and without subretinal hyperpigmentation (solid orange dots). Using
a selection tool on the Visual Field Modelling and Analysis (VFMA) software, volumetric sensitivity within regions of retinal pigmentation were extracted
from regions of pigmentation and nonpigmentation. The boxplots show the median value, quartiles, and range. hESC ¼ human embryonic stem cell; K ¼
thousand; P ¼ patient; RPE ¼ retinal pigment epithelial.
Mehat et al  hESC-Derived RPE Cell Transplantation in STGD1immunosuppressive medications to all participants for 13
weeks. We identified no overt clinical signs to suggest acute
or delayed rejection. Specifically, we noted no vitreitis, retinal
exudation or retinitis, vascular leakage, choroiditis, or cystoid
macular edema, although features of rejectionmay not always
be readily evident.21 We identified no change on clinical
examination or imaging after withdrawal of
immunosuppression, 12 weeks after the injection procedure.
A reduction in the pigmentation density at the site of
transplantation, evident in 2 participants (at month 6 in
patient 9 and at month 12 in patient 4) may reflect rejection
of pigmented donor hESC-derived RPE cells, although no
associated change in retinal functionwas apparent. The risk of
immune rejection may be reduced by use of autologous RPE
cells derived from induced pluripotent stem cells, althoughsuch cells nonetheless may be subject to rejection, and the
process of cell derivation specific to an individual presents
considerable logistical challenges.22
Reports of vision loss after intravitreal injection of
autologous adipose tissue-derived stem cells highlight the
potential for harm resulting from transplantation of cell
populations that are poorly characterized and controlled.23
In our study, intraocular administration of carefully
obtained hESC-derived RPE cells resulted in the develop-
ment of pigmented foci in the vitreous cavity in 2 partici-
pants and on the surface of the inner retina in 2 participants,
suggesting reflux of donor hESC-derived RPE cells from the
subretinal compartment into the vitreous cavity. Despite the
presence of preretinal or intravitreal pigmentation, no
associated adverse effect was evident.9
Ophthalmology Volume -, Number -, Month 2018The aim of intervention is to protect or improve aspects
of sight. In the current trial, all participants showed
advanced disease before intervention, with established
retinal degeneration and severe impairment of visual func-
tion. We measured no consistent progression of disease
during the 12-month trial; deterioration in the visual fields of
both eyes of 2 participants (patients 2 and 4) was apparent
on full-field perimetry, but was not evident on micro-
perimetry. Given the slow rate of progressive degeneration
at this advanced stage of disease, any protection against
further deterioration may be evident only after a more
extended period of observation.
We also sought to determine whether the function of
photoreceptor cells that are surviving but compromised
may improve after the provision of healthy supporting RPE
cells. In a previous trial of up to 150 000 hESC-derived
RPE cells in STGD1, variable improvements in VA were
measured in 3 of 8 eyes without secondary cataract,
although the mean difference in VA between the recipient
and contralateral eyes was not statistically significant.9 In a
subsequent trial in 2 participants with STGD1,
improvements in VA were reported in both the recipient
and contralateral eyes.10 In the present trial, we
administered up to 200 000 hESC-derived RPE cells and
measured retinal structure and function in detail using
microperimetry and SD OCT. Our findings demonstrate the
value of detailed analysis of spatial correlation of retinal
structure and function in determining with appropriate
sensitivity the impact of cell transplantation. We found no
significant benefit to retinal function at 12 months in the 12
participants. Although RPE cell transplantation theoreti-
cally may improve the function of overlying photoreceptor
cells, the potential for improvement is limited in this
particular population of participants by the severity of
established retinal degeneration.
The evidence of safety broadly supports the rationale for
further studies to explore the impact of intervention at an
earlier stage of degeneration when surviving photoreceptors
cells may stand to benefit with improved function and sur-
vival. However, instances of focally reduced sensitivity and
thinning in hyperpigmented retina at higher doses of hESC-
derived RPE cells suggest the potential for harm and indi-
cate that intervention at earlier stages of degeneration should
be approached with caution.References
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